I can speak from the licensing perspective around labelling.
Certainly, when a drug comes in for approval and it's clear that it has addictive or abuse potential, we spend a fair bit of time looking at the labelling and ensuring that when the product is authorized on the market the labelling is clear to both the prescribers and the pharmacists, and that in part three of the product monograph for consumers or patients, the risks of abuse and the potential outcomes of that abuse are clear, so if they're looking for information around the product it's there in the product monograph. We also make recommendations around how it should be stored, how it should be disposed of, and that sort of information. That information allows consumers, if they look for it, to be aware of the dangers of leaving the product around for others to use who don't understand those risks, and for the actual user to not inadvertently use it inappropriately and run into issues associated with that.